• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Express Scripts Eyeing Pricey Cancer Drugs Next

Article

Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.

Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.

"This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief medical officer of Express Scripts, told analysts during a conference call. "Cancer is different than any other disease, much more emotional."

Mr Miller said his company, the largest US pharmacy benefit manager, plans incremental moves and new tools to control cancer drug costs.

Read more at Reuters: http://reut.rs/1zhjXqP

Related Videos
Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"
Camilla Levister
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Video 12 - "Cost-Effective Medication Access in Demodex Blepharitis Management"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.